Kardigan Inc
KARDHealthcare|Biotechnology|USA
$24.55
+0.18 (+0.76%)
About
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.
Stock Price
+11.6%(1Y)
Pipeline Summary
4 total trials0
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
Recruiting: 3Completed: 1
Active Trials (3)
Study of Efficacy and Safety of Tonlamarsen in Participants With a Recent Hospitalization and a Concurrent Episode of Acute Severe Hypertension
NCT07511361Hypertension
Phase 2Recruiting
Enrollment: 140 participants
Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study
NCT07001800Moderate Aortic Valve Stenosis
Phase 2Phase 3Recruiting
Enrollment: 1,276 participants
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723Symptomatic Genetic Dilated Cardiomyopathy
Phase 2Phase 3Recruiting
Enrollment: 332 participants
BioScore
4.3/10
Cautious
Ownership
Recent Insider Trades
HRTG GPE, LLCBUY
2026-06-223,125,000 shares @ $16
BERNS PAUL LBUY
2026-06-221,250,000 shares @ $16
ARCH Venture Partners XIII, LLCBUY
2026-06-221,250,000 shares @ $16
Recent News
2026-07-13 11:34:33
2026-07-13 11:33:43
2026-07-04 00:37:26
2026-06-22 22:00:07
2026-06-20 19:55:22
Data last updated: Jul 13, 2026, 12:43 PM